Patents by Inventor Aleksandar Filip Radovic-Moreno

Aleksandar Filip Radovic-Moreno has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11389485
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: July 19, 2022
    Assignee: VOR BIOPHARMA INC.
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • Patent number: 11382932
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Grant
    Filed: April 5, 2021
    Date of Patent: July 12, 2022
    Assignee: VOR BIOPHARMA INC.
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • Publication number: 20220008476
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Application
    Filed: February 16, 2021
    Publication date: January 13, 2022
    Applicant: VOR BIOPHARMA, INC.
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • Publication number: 20210315936
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Application
    Filed: April 5, 2021
    Publication date: October 14, 2021
    Applicant: VOR BIOPHARMA, INC
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • Patent number: 11123294
    Abstract: Liposomal spherical nucleic acids that function as multivalent immune modulators are provided according to the invention. The liposomal spherical nucleic acids of the invention are useful prophylactic and therapeutic applications as well as research and diagnostic indications.
    Type: Grant
    Filed: September 12, 2019
    Date of Patent: September 21, 2021
    Assignee: Exicure Operating Company
    Inventors: Aleksandar Filip Radovic-Moreno, Richard Kang, Subbarao Nallagatla, Christopher C. Mader, Sergei Gryaznov
  • Publication number: 20210236559
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Application
    Filed: April 5, 2021
    Publication date: August 5, 2021
    Applicant: VOR BIOPHARMA, INC
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • Publication number: 20210228641
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Application
    Filed: April 5, 2021
    Publication date: July 29, 2021
    Applicant: VOR BIOPHARMA, INC
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • Publication number: 20210220407
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Application
    Filed: April 5, 2021
    Publication date: July 22, 2021
    Applicant: VOR BIOPHARMA, INC
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • Publication number: 20210102211
    Abstract: Aspects of the invention relate to spherical nucleic acid-based constructs and related methods and compositions thereof.
    Type: Application
    Filed: October 8, 2020
    Publication date: April 8, 2021
    Applicant: Exicure, Inc.
    Inventors: Aleksandar Filip Radovic-Moreno, Christopher C. Mader, Subbarao Nallagatla, Warefta Hasan, Aaron Love, Sergei Gryaznov
  • Patent number: 10925902
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Grant
    Filed: December 3, 2019
    Date of Patent: February 23, 2021
    Assignee: VOR BIOPHARMA, INC
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • Patent number: 10894963
    Abstract: Aspects of the invention relate to spherical nucleic acid-based constructs and related methods and compositions thereof.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: January 19, 2021
    Assignee: Exicure, Inc.
    Inventors: Aleksandar Filip Radovic-Moreno, Christopher C. Mader, Subbarao Nallagatla, Warefta Hasan, Aaron Love, Sergei Gryaznov
  • Patent number: 10837018
    Abstract: Aspects of the invention relate to spherical nucleic acid-based constructs and related methods and compositions thereof. The compositions of the invention are useful for activating agonists of nucleic acid interacting complexes, such as TLRs, stimulating an immune response, and treating diseases such as infectious disease, cancer, allergies, allergic diseases, and autoimmune disease.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: November 17, 2020
    Assignee: Exicure, Inc.
    Inventors: Aleksandar Filip Radovic-Moreno, Christopher C. Mader, Subbarao Nallagatla, Warefta Hasan, Aaron Love, Sergei Gryaznov
  • Publication number: 20200338130
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Application
    Filed: August 28, 2019
    Publication date: October 29, 2020
    Applicants: VOR BIOPHARMA, INC, PureTech Management, Inc.
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • Publication number: 20200318071
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Application
    Filed: March 10, 2020
    Publication date: October 8, 2020
    Applicants: VOR BIOPHARMA, INC, PureTech Management, Inc.
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • Publication number: 20200215179
    Abstract: Provided herein are new compositions including an inactivated pathogen and one or more adjuvant-loaded polymeric nanoparticles, wherein the adjuvant-loaded nanoparticles are bound to the inactivated pathogen. These compositions are useful for preventing and/or treating diseases caused by the specific pathogens, especially when administered to a subject's mucosal membranes.
    Type: Application
    Filed: November 11, 2019
    Publication date: July 9, 2020
    Inventors: Georg Stary, Aleksandar Filip Radovic-Moreno, Pamela A. Basto, Michael N. Starnbach, Robert S. Langer, Omid C. Farokhzad, Ulrich Von Andrian
  • Publication number: 20200138869
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Application
    Filed: August 28, 2019
    Publication date: May 7, 2020
    Applicants: VOR BIOPHARMA, INC, PureTech Management, Inc.
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • Publication number: 20200093865
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Application
    Filed: December 3, 2019
    Publication date: March 26, 2020
    Applicants: VOR BIOPHARMA, INC, PureTech Management, Inc.
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • Publication number: 20200069587
    Abstract: Liposomal spherical nucleic acids that function as multivalent immune modulators are provided according to the invention. The liposomal spherical nucleic acids of the invention are useful prophylactic and therapeutic applications as well as research and diagnostic indications.
    Type: Application
    Filed: September 12, 2019
    Publication date: March 5, 2020
    Applicant: Exicure, Inc.
    Inventors: Aleksandar Filip Radovic-Moreno, Richard Kang, Subbarao Nallagatla, Christopher C. Mader, Sergei Gryaznov
  • Publication number: 20200030381
    Abstract: Disclosed herein are compositions, methods, and kits for use in treating hematopoietic malignancies, the compositions, methods, and kits comprise a cytotoxic agent targeting cells expressing a lineage-specific cell-surface protein and a population of hematopoietic cells that express the lineage-specific cell-surface protein, the hematopoietic cells being manipulated such that they do not bind the cytotoxic agent.
    Type: Application
    Filed: February 28, 2018
    Publication date: January 30, 2020
    Applicant: VOR BIOPHARMA, INC
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • Patent number: 10485861
    Abstract: Provided herein are new compositions including an inactivated pathogen and one or more adjuvant-loaded polymeric nanoparticles, wherein the adjuvant-loaded nanoparticles are bound to the inactivated pathogen. These compositions are useful for preventing and/or treating diseases caused by the specific pathogens, especially when administered to a subject's mucosal membranes.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: November 26, 2019
    Assignees: President and Fellows of Harvard College, Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.
    Inventors: Georg Stary, Aleksandar Filip Radovic-Moreno, Pamela A. Basto, Michael N. Starnbach, Robert S. Langer, Omid C. Farokhzad, Ulrich Von Andrian